On March 20, 2019, Novo Nordisk announced the official submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral tablet semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) analogue. In trials, oral semaglutide caused reductions in both HbA1c and body weight when compared to placebo. Read more